Vifor (International) Ag

Vifor Ag

Michael Burgert

Stefan Reim

Wilm Buhr

Susanna Burckhardt

Franz Dürrenberger

Aris Kalogerakis

Erik Philipp

Peter Geisser

Felix Funk

Jörg Schmitt

Thomas Bark

Camillo Canclini

Simona Mayer

Diana Sieber

Katrin Schwarz

Christopher John Yarnold

Cristina Lecci

John Scott

Jon Shepherd

Susan Boyce

Paula Pena

Vania Manolova

Richard Jarjes-Pike

Fritz Blatter

Giuseppe Lapadula

Collin D Morris

Jorg Schmitt

Peter Otto Geisser

Jürgen Klotz

Franz Durrenberger

The invention relates to novel salts of compounds of the general formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia, sickle cell disease and hemochromatosis.

Ferroportin-inhibitor salts

The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

Ferroportin inhibitors

The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis. 

The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis. 

The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias

Fe(III)-pyrazine complex compounds for treatment and prophylaxis of iron-deficiency phenomena and iron-deficiency anaemia

Growing community of inventors

Friedrichshafen, Germany

Michael Burgert